Annals of Oncology Advance Access published online on February 13, 2007
Annals of Oncology, doi:10.1093/annonc/mdl500
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome
1 Laboratoire de Biologie Médicale, Centre Georges François Leclerc, Dijon
2 Unité de biostatistiques et d'épidémiologie, Centre Georges François Leclerc, Dijon
3 Laboratoire de Biologie, Centre Henri Becquerel, Rouen
4 Laboratoire de Biologie, Institut Claudius Regaud, Toulouse
5 Laboratoire de Biologie Clinique, Institut Jean Godinot, Reims
6 Laboratoire de Radioanalyse, Centre Paul Papin, Angers
7 Laboratoire de Radioanalyse, Institut Bergonié, Bordeaux
8 Laboratoire d' Oncobiologie, Centre René Gauducheau, Nantes
9 Laboratoire d'Oncobiologie, Centre René Huguenin, Saint-Cloud, France
* Correspondence to: Dr J. M. Riedinger, Laboratoire de Biologie Médicale, Centre GF Leclerc, 1 rue du Pr Marion, 21034 Dijon cedex, France. Tel: +33-3-80-73-75-10; Fax: +33-3-80-73-75-26; E-mail: jriedinger{at}dijon.fnclcc.fr
Background: CA 125 assays enable treatment response monitoring in ovarian cancer.
Patients and methods: This multicentric study was carried out to assess the prognostic value of the CA 125 change after the first and the second courses of induction chemotherapy (CT). Of the 494 stage IIc–IV patients, 194 had a surgical second look, 397 (80.4%) relapsed and 382 (77.3%) died from cancer. Median (range) follow-up time was 34 months (3–215 months).
Results: In Cox models, CA 125 change after the first course (P < 0.0001), residual tumour (P = 0.003), CA 125 before the second course (P = 0.025) and patients' age (P = 0.048) were independent prognostic factors for overall survival (OS). A normal CA 125 before each of the two first CT courses or a CA 125 decrease >50% after the first course with a normal CA 125 before the second course identify patients with good prognosis. Both criteria retained a significant value in predicting second-look findings by univariate and multivariate analysis (P < 0.0001).
Conclusion: Among well-established prognostic factors in ovarian cancers, the CA 125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and OS.
CA 125, chemotherapy, ovarian cancer, prognosis, second look, survival
Received for publication November 10, 2006. Revision received December 12, 2006. Accepted for publication December 15, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann. Onc., February 1, 2009; 20(2): 294 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Lowe, C. Shah, E. Wallace, G. Anderson, P. Paley, M. McIntosh, M. R. Andersen, N. Scholler, L. Bergan, J. Thorpe, et al. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2480 - 2487. [Abstract] [Full Text] [PDF]
|
|